Ogt and Intelliseq Forge Partnership To Advance Clinical and Biological Insight From Ngs Data
Complete the form below to unlock access to ALL audio articles.
OGT, a Sysmex Group Company, is delighted to announce its new partnership with Intelliseq, a genome informatics company and innovative provider of Next-Generation Sequencing (NGS) analysis solutions. This collaboration combines OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a thorough and comprehensive NGS workflow—from sample to report. This advancement will greatly enhance lab productivity by automating the interpretation of NGS data and deliver actionable insights into cancer.
“We are excited about this partnership with Intelliseq. With the biological and clinical interpretation provided by Intelliseq, SureSeq users will have access to a comprehensive NGS solution that provides more meaningful clinical insight,” said Adrian Smith, CEO of OGT. “This partnership ensures that SureSeq users can examine any genomic content they want, while receiving the most up-to-date insight from a wide variety of clinical and biological databases.”
Similarly, CEO of Intelliseq, Klaudia Smolana, shared excitement, adding, “Our mission at Intelliseq is to simplify genome data analysis and interpretation and make it more insightful, automated and scalable. Partnering with OGT is an exciting opportunity for Intelliseq to expand the reach of our advanced NGS reporting solutions. Our technology combined with OGT’s expertise in NGS solutions will enable laboratories to unlock the full potential of their genomic data and offer a complete analysis. We look forward to the positive impact this collaboration will have on the genomics community.”
This partnership between OGT and Intelliseq exemplifies a shared commitment to innovation and customer-centric solutions. Both companies believe that by combining their strengths, they can provide laboratories worldwide with the tools they need to deliver accurate, personalized and actionable insights.